shortening the distance from lab to life. health corporate...shortening the distance from lab to...
TRANSCRIPT
SHORTENING THE DISTANCE FROM LAB TO LIFE.®
Syneos HealthTM. Creating Biopharmaceutical
Acceleration.
One year ago, INC Research and inVentiv Health came together to create Syneos Health, the industry’s only true end-to-end solution. Today, we are a seamless global company that combines world-renowned clinical and commercialization capabilities with today’s advanced science, data and business technologies to make possible real advances in biopharmaceutical development.
BAMTM
The business model that sets Syneos Health apart from all the rest.
Syneos Health is the only company in the biopharmaceutical services industry purpose-built to create greater success for our customers. At Syneos Health, clinical and commercial live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.
We call this new way of collaborative working the Biopharmaceutical Acceleration ModelTM or BAMTM.
How does it work? BAM is an end-to-end concept, working across our clinical and commercial capabilities and driven by each and every one of our approximately 24,000 employees. Importantly, it also incorporates many unique Syneos Health disciplines including the Trusted Process®, Syneos OneTM, the Syneos Health Data
Trusted Process®
Medication Adherence
Early PhaseTranslational Sciences
Real World Evidence
Advisory & Strategic Consulting Services
Syneos One
Dynamic Assembly
FSP 360 — Hybrid — Full Service
Behavioral Insights
Therapeutic and Acceleration Insights
TM
TM
Deployment SolutionsCommunications
Biopharmaceutical Acceleration ModelTM
Lake Ecosystem, Real World Evidence and our deep therapeutic expertise — each providing a constant stream of insights focused on two critical areas: patient behavior and process acceleration.
These insights, along with our unique approach to data and digital, which we call Dynamic AssemblyTM, allow us not only to solve problems, but also solve them more quickly, increasing the likelihood of regulatory approval and maximizing commercial success. At Syneos Health, we believe that BAM is the future of biopharmaceutical development. But more importantly to our customers, it is the key to shortening the distance from lab to life®.
CO
MM
ER
CIA
LIZ
ATI
ON
PR
OD
UC
T LA
UN
CH
PH
ASE
IIb
/III
PH
ASE
IIa
PH
ASE
IE
AR
LY P
HA
SE
SYN
EO
S O
NE
TM
TRA
NSL
ATI
ON
AL
SCIE
NC
ES
RE
AL
WO
RLD
EV
IDE
NC
E
STR
ATE
GIC
CO
NSU
LTIN
G –
CO
MM
ER
CIA
L M
AR
KE
T A
CC
ESS
, ME
DIC
AL,
CO
RP
OR
ATE
DE
VE
LOP
ME
NT
BIO
AN
ALY
TIC
AL
AN
D B
IOM
AR
KE
R S
ER
VIC
ES
ME
DIC
AL
ED
UC
ATI
ON
PH
ASE
I C
LIN
ICA
L D
EV
ELO
PM
EN
T
AD
VE
RTI
SIN
G –
DIG
ITA
L C
OM
MU
NIC
ATI
ON
S –
SOC
IAL
ME
DIA
PH
ASE
I P
RO
OF
OF
CO
NC
EP
T D
EV
ELO
PM
EN
TC
ON
TRA
CT
SALE
S TE
AM
– M
SLs
– C
LIN
ICA
L N
UR
SE E
DU
CA
TOR
S –
SALE
S SU
PP
OR
T
PU
BLI
C R
ELA
TIO
NS
– P
UB
LIC
AFF
AIR
S –
PO
LIC
Y A
ND
AD
VO
CA
CY
PH
ASE
IIa
– I
II C
LIN
ICA
L D
EV
ELO
PM
EN
T
BR
AN
DIN
G
PH
ASE
III
b –
IV
CLI
NIC
AL
DE
VE
LOP
ME
NT
ME
DIC
ATI
ON
AD
HE
RE
NC
E
FSP
360
AN
D G
LOB
AL
CLI
NIC
AL
STA
FFIN
G S
OLU
TIO
NS
SER
VIC
ES
Fast
er p
roce
sses
, sm
ooth
er s
yste
ms
and
mor
e ac
tiona
ble
insi
ghts
are
just
som
e of
the
bene
fi ts
Syne
os H
ealth
and
Bio
phar
mac
eutic
al A
ccel
erat
ion
can
brin
g to
a m
arke
tpla
ce th
at g
row
s in
crea
sing
ly c
ompl
ex a
nd c
ompe
titiv
e ea
ch d
ay.
Inte
grat
ed S
olut
ions
= B
iop
harm
aceu
tica
l Acc
eler
atio
n
Syneos One™
One team, guiding your asset from concept to commercialization.
Syneos One is our most powerful BAM expression. Utilized by a unique group of highly motivated Syneos Health customers, Syneos One is our end-to-end off ering that gives customers true control and ownership of their asset. Our Syneos One team, experienced Asset Strategists who are highly adept at closing gaps and creating timesaving effi ciencies, leads the way from strategy to development and execution and from clinical to full commercialization, ensuring that data, knowledge and insights move back and forth along the continuum. This constant sharing and oversight allow us to achieve even greater effi ciencies, speed and program risk reduction — all with the goal of helping our customers maximize ROI.
Dynamic Assembly™
Intentionally source agnostic to remain nimble and ahead of the curve.
Your business is evolving faster than ever before, and so is technology. For that reason, we believe the right strategy to leverage data and technology for success is via an open, source-agnostic and highly fl exible architecture. We call this Dynamic Assembly. It allows us to address the nuances of each customer, trial protocol and product launch quickly rather than being forced to bend legacy in-house assets to a task they weren’t originally designed to deliver.
The foundation of our Dynamic Assembly Strategy is the Syneos Health Data Lake Ecosystem. Built without the constraints of legacy technology and architecture, it features our proven Syneos Health-designed data ingestion process focused on quality and incorporates decades of Syneos Health learnings and best practices. Our Data Lake links vast amounts of data from diverse sources — clinical and commercial, internal and external, structured and unstructured — with the ability to harmonize data and concepts working through the Hortonworks Data Platform, which includes Hadoop software. This ability to synthesize multiple data types and sources, creating new “asset-customized” data, propels our BAM model, allowing us to achieve deeper patient behavioral learnings and insights. Our unique, highly nimble model delivers exactly what customers need, where and when they expect it and in ways they can easily understand and act upon. Not surprisingly, Dynamic Assembly aff ects all phases of drug development, smoothing the process, reducing time to market and helping to improve ROI for our customers.
Real World Evidence (RWE)We live and breathe the real world. Always have, always will.
We are living in the era of RWE. Every day we see more proof of the power and business impact of strategic evidence management. The combination of incredible data availability, rapid tech advancements, the 21st Century Cures Act and a growing desire for true patient-centricity is leading not only regulators, but also an entire industry to embrace the use of RWE. At Syneos Health, our experience with Real World Evidence and insights spans decades. And because we are purpose-built to utilize continuous insights across our clinical and commercial organizations, our unique RWE approach drives better solutions, from regulatory to operations and patient adherence. In fact, our Biopharmaceutical Acceleration Model is fueled by RWE across all phases of the product lifecycle to create real value for the customer — be it generating compelling evidence packages for access and reimbursement, reducing training costs or better understanding the entire patient journey. But perhaps most importantly, Syneos Health has the know-how and experience to help our customers transform RWE from the latest healthcare acronym into maximized outcomes and ROI.
The Trusted Process®
A proven and predictable system for getting the job done.
Syneos Health established the Trusted Process more than a decade ago as a disciplined methodology for planning, problem solving and execution. It acts as the enterprise- wide framework for delivery excellence that underpins BAM. The Trusted Process is repeatable, predictable, highly reliable and has been proven in our clinical practices to meet critical development milestones faster than the industry average. That’s why it is rapidly being expanded across the entire spectrum of Syneos Health solutions to optimize engagement of medical and patient communities after product approval.
Therapeutic DepthSome insights only therapeutic alignment can generate.
Syneos Health is built on our firm belief in therapeutic depth. We assemble teams in which members, from CRAs to senior management, are experts in the same therapeutic area. This team approach delivers much stronger insights into the therapeutic environment, the competitive landscape and the patient population. In other words, better answers, faster.